AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deNOV 32 min read$TEVA

Medincell - UZEDY: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M

Medincell's partner Teva reported $85M in Q3 2026 U.S. net sales for UZEDY, up 96% year-on-year. Teva raised its 2026 revenue outlook to $290-310M. Medincell receives royalties and may earn up to $105M in milestones. UZEDY is the fastest-growing long-acting schizophrenia treatment in the U.S.

Original reporting
finanznachrichten.de
Published Nov 3, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TEVA
Bullish
high confidence
Mentioned
$TEVA
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The data provides fresh guidance that can shift market expectations for Teva and its partners.

02

Market read

First‑time disclosure of strong sales growth and raised outlook for a key schizophrenia drug, likely influencing Teva's share price.

03

What to watch

Potential regulatory scrutiny on long‑acting injectables or competition from upcoming olanzapine LAI could temper growth.

Relevance 7/10Novelty 7/10Timing: today

Background

The press release announces Q3 2026 UZEDY sales and an increased 2026 revenue outlook, marking the first public disclosure of these figures.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva reported UZEDY U.S. net sales of $85M in Q3 2026, up 96% YoY, and raised its 2026 revenue outlook to $290‑310M.

Expected impact

likely upward pressure as investors price in higher sales and outlook

Evidence & confidence

The 96% YoY sales jump and raised outlook are fresh, material data that can move the share.

Market effects

Sector

Strengthens outlook for the long‑acting injectable schizophrenia market and may benefit peers using similar technology.

Regional

U.S. specialty pharma segment sees a boost from higher UZEDY sales.

Global

Highlights the commercial success of BEPO technology, relevant for global biotech investors.

Counterpoint

What could challenge this read

If the sales surge is driven by temporary market conditions, the upside may be limited.

Key entities

  • Company
    Teva Pharmaceuticals

    U.S. pharmaceutical partner reporting sales and outlook.

  • Company
    Medincell

    Owner of BEPO technology licensing UZEDY to Teva.

Read at source← All news

Related articles

NOV 3
$TEVAHighAI 9/10

Teva Q3 2026 slides: biopharma shift lifts margins to 58.7%

Teva Pharmaceuticals (NYSE:TEVA) reported Q3 2026 revenues of $4.4B and adjusted EPS of $0.86, beating estimates. Gross margin rose to 58.7% due to a shift toward biopharma. Key products like AUSTEDO, UZEDY, and AJOVY drove growth. The company raised full-year guidance and announced FDA approval for WELTRUZA, a new schizophrenia treatment.

investing.com3 min
NOV 3
$TEVAMed

Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars

Teva Pharmaceuticals and Samsung Bioepis agreed to license and commercialize two FDA-approved biosimilars in the U.S. Teva will handle sales, with Samsung retaining manufacturing. The deal includes upfront payments, milestones, and profit sharing. Closing is expected by the end of 2026, with rights to etanercept-ykro transferring at that time and infliximab-abda in Q3 2027.

pharmexec.com3 min
NOV 3
$TEVAHighAI 9/10

Teva again raises guidance as branded drugs lift revenue

Teva Pharmaceutical (TEVA) reported Q3 revenue of $4.4B, beating estimates. It raised 2026 revenue guidance to $16.7-$17B. Branded drugs grew 33%, with Austedo, Ajovy, and Uzedy driving sales. GAAP net profit was $233M, while non-GAAP was $1B. Debt refinancing extended maturity to 6.3 years. CEO highlighted FDA approvals and biosimilars agreement with Samsung Bioepis.

en.globes.co.il5 min
NOV 3
$QUREMed

UniQure gets an FDA decision date; Teva scraps brain drug study

UniQure's Huntington's disease gene therapy application is under FDA review with a decision expected by May 1. Teva Pharmaceuticals halted a mid-stage study of emrusolmin for multiple system atrophy due to futility. Bright Minds Biosciences' antiseizure drug trial was partially halted by the FDA. Specific Biologics raised $35M in Series A funding for ALS therapy trials. CinRx Pharma and Graviton BioScience formed a joint venture to develop cardiovascular drugs.

finance.yahoo.com6 min
NOV 3
$TEVAHighAI 8/10

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA): Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial…

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION

SEC EDGAR 8-K2 min